THAR Stock Overview
A clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tharimmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.56 |
| 52 Week High | US$71.85 |
| 52 Week Low | US$1.84 |
| Beta | 1.45 |
| 11 Month Change | 24.65% |
| 3 Month Change | -10.49% |
| 1 Year Change | -94.06% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.80% |
Recent News & Updates
Shareholder Returns
| THAR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.0% | 2.4% | 2.2% |
| 1Y | -94.1% | 16.2% | 31.7% |
Return vs Industry: THAR underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: THAR underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| THAR volatility | |
|---|---|
| THAR Average Weekly Movement | 23.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THAR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: THAR's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 3 | Randy Milby | www.tharimmune.com |
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
Tharimmune, Inc. Fundamentals Summary
| THAR fundamental statistics | |
|---|---|
| Market cap | US$3.88m |
| Earnings (TTM) | -US$10.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs THAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THAR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.85m |
| Earnings | -US$10.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THAR perform over the long term?
See historical performance and comparison